Neuronetics STIM 深 沪
等待开盘 10-28 09:30:00 美东时间
3.09
-0.030
-0.96%
华盛通- 最 高3.1673
- 今 开3.14
- 成交量 79.77万股
- 最 低 3.00
- 昨 收 3.12
- 总市值 2.04亿
- 52周最高 5.92
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.52
- 委 比 -74.42%
- 总股本 6612.48万
- 历史最高 39.39
- 量 比 0.85
- 振 幅 5.36%
- 历史最低 0.52
- 每 手 1
- 风险率 1.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多New York Medicaid To Cover Neuronetics' TMS Therapy For Major Depressive Disorder Starting October 2025
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of
09-17 20:41
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
New York State Medicaid will begin covering Transcranial Magnetic Stimulation (TMS) services for adults with major depressive disorder (MDD) starting October 1, 2025, for fee-for-service members and November 1, 2025, for Managed Care Plan enrollees. This decision benefits nearly 1 million fee-for-service Medicaid members and over 4.4 million Managed Care参保者, making TMS more accessible to those who need it most. TMS is an evidence-based, non-drug ...
09-17 12:32
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-13 19:10
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
Neuronetics Affirms FY2025 Sales Guidance of $149.000M-$155.000M vs $150.673M Est
Neuronetics (NASDAQ:STIM) affirms FY2025 sales outlook from $149.000 million-$155.000 million to $149.000 million-$155.000 million vs $150.673 million estimate.
08-05 19:07
Neuronetics Sees Q3 Sales $37.000M-$39.000M vs $38.395M Est
Neuronetics (NASDAQ:STIM) sees Q3 sales of $37.000 million-$39.000 million vs $38.395 million analyst estimate.
08-05 19:07
Neuronetics Q2 EPS $(0.15) Misses $(0.08) Estimate, Sales $38.108M Beat $36.612M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.08) by 94.81 percent. This is a 54.55 percent increase over losses of $(0.33) per share from the
08-05 19:06
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
Neuronetics, Inc. announced that its CEO, Keith Sullivan, will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The presentation will be available to attendees for 14 days post-event. Neuronetics specializes in neurohealth therapies, with NeuroStar Advanced Therapy as its flagship product, offering non-drug treatment for mental health conditions. Its Greenbrook centers have delivered over 7.4 million treatments f...
08-04 20:30
Neuronetics Publishes Real-World Data Showing Antidepressant Effects Of NeuroStar TMS In Adolescents And Young Adults
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders,
07-30 20:33
